Key Takeaways
- Margin recovery story intact: EBITDA margin reached 13.7%, the fifth consecutive quarter of improvement and a 6.5x increase over the same quarter last year, driven by distribution gains and manufacturing efficiencies.
- Distribution segment is the engine: Strong principal support and stable domestic demand are driving volumes, with the US oil and gas export decline already reversing this quarter.
- Manufacturing pivot is slow but real: NMA commercial sales began, polyacrylamide solids R&D nears completion, and toll manufacturing talks are advancing, but timelines stretch 2–2.5 years and R&D has no definite endpoint.
- Management transition is a live variable: The founder moved to Non-Executive Chairman to empower the next generation; he claims growth has improved since his departure, but the call offered no operational proof.
- What to watch next quarter: Whether the promised 20–30% volume jump materializes, whether polyacrylamide solids R&D actually completes, and whether the new management team can convert the pipeline of toll and specialty projects into signed agreements.
Margin & Financial Performance
- EBITDA margin trajectory: Margins rose to 13.7% in Q3, marking the fifth straight quarter of improvement; compared to the same quarter last year, EBITDA margin has increased nearly 6.5x.
- Distribution margin drivers: Margins improved approximately 20% QoQ due to better material planning, a favorable product mix, and improved supply from principals for higher-margin products like ethanolamine and isophthalic acid.
- Manufacturing margin resilience: Margins improved despite lower realizations in both domestic and international markets, because the company executed better and more prudent raw material planning.
- Revenue growth: Consolidated revenue grew 12%, supported by both segments.
Ambarish Daga: "This is the 5th consecutive quarter in which we have been able to increase our EBITDA margins and quarter-on-quarter compared to the same quarter of the previous financial year, it's almost a 6½ fold increase in the EBITDA margin."
Distribution Business
- Current quarter outlook is strong: Demand is stable and principals are providing strong backing for key products including resorcinol, metacresol, and ethyleneamines, which should add substantial volumes and revenue this quarter.
- US export recovery underway: The decline in the US oil and gas sector, which had depressed distribution exports in prior quarters, has reversed during the current quarter, supporting substantial segment growth.
- Ethyleneamines momentum: Ethyleneamines has been a very significant product in the distribution portfolio, with substantial volume growth seen in the last quarter and a promising outlook going forward.
- New markets push: The team is fully geared to add new markets and new customers for each product segment, including ethyleneamines.
- Export decline in Q3: Distribution exports declined QoQ because of the slowdown in the US Oil and Gas sector; manufacturing exports were more or less flat.
Manufacturing: Current Products & Challenges
- Acrylamide powder under pressure: The business continues to be impacted by dumping from China; the company is addressing this by concentrating more on exports.
- Polyacrylamide liquids demand subdued: The ceramic tile industry at Morbi has been hit by high energy costs and up to a 40% dip in export business due to geopolitical issues and Red Sea logistics, reducing demand for binder.
- NMA commercial milestone: The company successfully obtained approval and validation from key customers domestically and internationally and has started commercial sales to one of the largest NMA customers in India.
- Volume picture: For Q3, manufacturing volumes were flattish in some products; for the 9-month period, volumes are higher than the previous year, and the company expects to beat prior-year figures by year-end.
- Acrylamide solid export dynamics: Despite disruptions in certain markets from the Red Sea crisis, overall export for acrylamide solid is expected to increase this quarter because the company is reaching newer customers and gaining product acceptance; current quantities are low, leaving room for further penetration.
- Revenue potential at full utilization: At full utilization of the four current products and at current market prices, manufacturing revenue could be between ₹300 to ₹400 crores.
Ambarish Daga: "Although there will be some disruption in certain markets for the acrylamide solid, however, despite these global headwinds and these challenges, our overall export for acrylamide solid is expected to increase during this quarter, because we are reaching newer customers, we are getting our acceptance for the product."
R&D Pipeline & New Projects
- Polyacrylamide solids progress: Development on the software side (product and process) has been completed; R&D activity on the hardware side (technology and manufacturing aspects) is expected to complete very soon.
- Specialty chemicals project: Discussions are in advanced stages for a specialty chemicals project at the Jhagadia site with collaboration from a Japanese principal.
- Toll manufacturing talks: Two toll manufacturing projects related to acrylamide chemistry are under discussion with US and European countries; one falls under the category of polyacrylamide liquid applications for new grades.
- Polyacrylate dispersant: The company has developed a polyacrylate-based dispersant, with trials already underway with some customers.
- Polyacrylamide liquid portfolio expansion: The company is actively working on introducing different grades for other applications to ensure a more diversified product basket and higher capacity utilization.
- Toll manufacturing timeline: The process, from intent to cooperate through technical discussions, feasibility studies, and environmental clearance certifications, can take anywhere between 2 to 2.5 years.
- R&D timelines are inherently uncertain: Management stated that R&D can take years to finalize and that a definite timeline cannot be defined; quarter-to-quarter timelines cannot be very definitive.
Ambarish Daga: "R&D is something which can take years and years to finalize. So, that is not something where a definite timeline can be defined."
Capital Allocation & Infrastructure
- Polyacrylamide solids plant cost: Once technology and processes are finalized, the project will require between ₹60 to ₹100 crores; the method of raising capital will be chosen at the appropriate time.
- 20-acre land acquisition: The company is buying 20 acres of land for future projects that have not yet been discussed, to ensure land availability does not become an impediment to future manufacturing expansion; current projects can be accommodated at the existing Jhagadia site.
- Low-CapEx advantage: The company's plant is designed so that additional capacity increases require very small incremental capital; the idea is to avoid large capital outlays once initial capacities are utilized to the right extent.
- New R&D facility: The company is looking at setting up a new R&D facility in and around Mumbai.
- Fund-raising clarification: Management stated the company has never said it intends to raise ₹100 crores; it has only mentioned the cost of a project, with the method of funding yet to be discussed.
Anup Jatia: "the company has never said that they intend to raise 100 crores. We have always mentioned the cost of a project and we have always mentioned that the method of funding the projects are yet to be discussed. We have never said we are interested in raising funds."
Management Transition
- Anup Jatia re-designated: Mr. Jatia has moved from an executive role to Non-Executive Chairman; he is no longer involved in day-to-day affairs but remains available to provide support as part of the board.
- Rationale: The change was made to give the existing team, including Ambarish, Bhavesh, and the KMPs, an opportunity to grow and expand their own strengths.
- No promoter change: There is no change in promoters and no intention to change promoters.
- Founder's view on growth: Mr. Jatia stated he has seen better growth within the organization after his departure and believes growth is getting even better at the company.
- Private matter: When asked whether there were personal reasons for the move, management declined to comment, calling it a private matter.
Anup Jatia: "if by continuing to remain in an executive position, the existing team there, including Ambarish and Bhavesh and our, the KMPs at the company, do not really get an opportunity to grow and to expand their own strengths as well. So, the idea is, basically to give them… to have the reins now into the next generation team and for me to move out, so that they can have the ability to excel and the ability to grow the company as well."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Volume growth | 20 to 30% jump in overall volumes | Q4 FY24 (current quarter) |
| Distribution segment growth | Substantial growth expected, driven by stable demand, increased supplies, and strong principal support | Q4 FY24 (current quarter) |
| US export recovery | Export volumes expected to pick up after a few quarters of subdued demand | During Q4 FY24 |
| Acrylamide solid exports | Overall export expected to increase despite Red Sea disruptions, via new customer penetration | Q4 FY24 |
| NMA volumes | Substantial growth in annual volumes expected | Upcoming quarters |
| Polyacrylamide solids R&D | R&D activity expected to complete very soon | No date (VAGUE-TIMELINE) |
| Toll manufacturing projects | Process from intent to clearance takes 2 to 2.5 years | 2–2.5 years from start |
| Polyacrylamide solids plant investment | ₹60 to ₹100 crores required once technology is finalized; funding method to be decided | At time of implementation (undated) |
| Manufacturing revenue potential | ₹300 to ₹400 crores at full utilization of four current products at current market prices | At full utilization (undated) |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Revenue growth (consolidated) | 12% YoY |
| EBITDA margin | 13.7%, 5th consecutive quarter of increase; almost 6.5x YoY |
| Distribution revenue share | 65% of total revenue |
| Exports share | 27% of total revenue, down QoQ due to subdued US Oil and Gas demand |
| Distribution margin growth | ~20% QoQ |
| Top 5 products revenue share | 78% to 80% of distribution top line |
| Top 5 products profit share | 60% of distribution profits |
| Manufacturing volumes | Flattish QoQ |
| Manufacturing sales | ₹20 cr |
| Current ratio | Over 8x |
| Debt-to-equity | Almost negligible |
| Acrylonitrile raw material price range | $1,100 to $1,200 per ton during the quarter |
| Morbi tile export decline | Up to 40% impact |
| Promoter holding | 75% |
| Q4 FY24 volume growth outlook | 20% to 30% jump expected |